INFLIXIMAB BIOSIMILAR VERSUS METHOTREXATE FOR THE
TREATMENT OF MODERATE TO SEVERE PSORIASIS
MARIA-ISABELA SÂRBU1#, MIRCEA TAMPA1,2#, CLARA MATEI1#*, CRISTINA-IULIA MITRAN1,2#, MĂDĂLINA-IRINA MITRAN1,2#, SILVIU PIŢURU1#, CORINA SILVIA POP3#,
GABRIEL ŞARAMET1#, SIMONA-ROXANA GEORGESCU1,2#
1“Carol Davila” University of Medicine and Pharmacy, Bucharest, Romania
2“Victor Babeş” Clinical Hospital for Infectious Diseases, Bucharest, Romania
3Emergency University Hospital, Bucharest, Romania
*corresponding author: matei_clara@yahoo.com
#All authors have equally contributed to this paper.
Download Full Article

Abstract:
Psoriasis is a chronic, immune-mediated condition associated with severe impairment in the patient’s quality of life. A
biosimilar is a biological medicine that is highly similar to another already approved biological medicine and is authorized in
accordance with the same standards as all biological treatments. In this study we compared the efficacy of infliximab
biosimilar to that of methotrexate in patients with plaque type psoriasis. 16 patients treated with infliximab biosimilar and 30
patients treated with methotrexate were included. The severity of the disease was measured using the Psoriasis Area and
Severity Index (PASI) at the beginning of the treatment and then at 3, 6, 9 and 12 months. The primary efficacy endpoint was
the proportion of patients achieving an improvement of at least 75% in the PASI (PASI 75). At the end of the study we found
that the efficacy of infliximab biosimilar, as measured by PASI 75, was significantly higher than the efficacy of methotrexate
and the results were noticed from the very first 3 months of treatment.

Top